SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors react to the company's annual shareholder meeting and news regarding a potential acquisition of eBay, sparking intense debate over whether these developments signal a strategic pivot or further dilution. The community remains deeply divided, with bulls highlighting long-term turnaround efforts while bears and frustrated retail holders point to stagnant price action and past failed squeeze predictions.

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is trending as investors react to a significant clinical data milestone regarding the stabilization of kidney function for its lead drug, Atacicept, alongside optimism surrounding its regulatory pathway. The community is actively debating the stock's potential for a short squeeze due to high short interest, while institutional investors closely monitor its competitive positioning in the IgA nephropathy market.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing a significant surge in momentum driven by a combination of index rebalancing, active share buybacks, and high short interest that has led the community to draw parallels to previous parabolic short squeeze setups. Traders are closely monitoring a tight, institutional-heavy float as they anticipate that sustained upside could force short sellers to cover, potentially accelerating price movement toward key resistance levels.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is under pressure as reports of Chinese AI startup DeepSeek developing custom chips to reduce reliance on foreign hardware trigger sector-wide anxiety about the sustainability of the AI infrastructure buildout. Despite these competitive headwinds, the community remains divided, with bulls viewing the dip as a value-buying opportunity based on strong fundamental demand, while bears point to persistent volatility and rotational shifts as signals of a cooling AI cycle.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending as investors react to a solid earnings report and raised revenue guidance, fueling community speculation about a potential buyout or major partnership as the company approaches self-sustainability. Discussions remain heavily focused on the blockbuster potential of Recorlev and the upcoming Phase 3 development of their once-weekly injectable levothyroxine candidate, XP-8121.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corp

Arbutus Biopharma is currently capturing investor attention following the FDA's decision to grant fast track designation to its lead chronic Hepatitis B candidate, imdusiran. The community is actively debating the stock's long-term valuation in light of this clinical progress, alongside ongoing patent litigation catalysts against major pharmaceutical firms and potential strategic takeover interest.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is trending as institutional interest surges following a $14 price target initiation by Mizuho and confirmed Breakthrough Therapy Designation for NXC-201. The community is actively discussing the potential for a strategic buyout or accelerated BLA timeline, with many investors focusing on the company's differentiated ex vivo CAR-T platform as a major differentiator in the AL amyloidosis space.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is surging as investors speculate on a potential buyout amid strong commercial growth from its Briumvi franchise and recent expansion into new indications like schizophrenia. The community is actively discussing the stock's impressive momentum, significant short interest, and the removal of potential acquisition barriers as primary drivers for a potential future premium transaction.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is gaining significant investor attention as recent Phase 3 data and potential FDA approval milestones for its lead psychedelic program, COMP360, strengthen the company's commercial outlook for treatment-resistant depression. Community discussion is heavily focused on the stock's role as a first-mover in a nascent sector, with many participants tracking institutional interest, the upcoming NDA submission, and the potential for a transformative impact on psychiatric medicine.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare Inc. (NET) is generating significant momentum as analysts highlight its critical role in the AI infrastructure landscape and edge computing market. Investors are closely monitoring the stock's consolidation patterns near all-time highs while engaging in active debates regarding its aggressive growth strategy and positioning as a foundational layer for autonomous AI agents.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


alliedloftslondon

Nhà cái uy tín